ADARx Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ADRX)

Q: What does CUSIP 00654F105 represent in this 13F holders report?

CUSIP 00654F105 is the security identifier for ADRX - ADARx Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held ADRX - ADARx Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in Q3 2026?

1 institutional investor reported ADRX - ADARx Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share for Q3 2026. Use the holders table for investor-level position and value details.

CUSIP: 00654F105

Q3 2026 13F Holders as of 30 Sep 2026

Security type / class: Equity / Common Stock, par value $0.0001 per share
Total 13F shares: 20,000
Total 13F value: $398,800
Share change: +20,000
SEC-reported price per share: $19.94
Number of holders: 1
Value change: +$398,800
Number of buys: 1
Shares outstanding: 106,834,730

Security key

00654F105

Report period

Q3 2026

Institutions

Top holders

ADRX full security history Ownership snapshot Full 13F holder table ADARx Pharmaceuticals, Inc. SEC filings

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 00654F105

Recent filing periods:

Q3 2026

Ownership snapshot

Top reported holders of ADRX - ADARx Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

ORBIMED ADVISORS LLC

Disclosed value leader

LAV Biosciences Fund V, L.P.

Comparable rows

4/15

Latest evidence

30 Sep 2026

3/4/5 13D/G Lead comparable stake: 14% 11 rows are not safely comparable across share classes. 13D/G row: ORBIMED ADVISORS LLC Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.

4 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.

Comparable ownership Top 4

ORBIMED ADVISORS LLC 14%

LAV Biosciences Fund V, L.P. 11%

SR ONE CAPITAL MANAGEMENT, LLC 9.3%

BCLS Fund III Investments, LP 6.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
ORBIMED ADVISORS LLC	3/4/5 13D/G Director, 10%+ Owner 3/4/5 13D/G	14% Reported 13D/G · 28 Sep 2026	— 588,235 shares	—	28 Sep 2026
LAV Biosciences Fund V, L.P.	13D/G 3/4/5 Yi Shi · 10%+ Owner 13D/G 3/4/5	11% Reported 13D/G · 30 Sep 2026	$244,762,639 11,858,655 shares	$0	30 Sep 2026
SR ONE CAPITAL MANAGEMENT, LLC	3/4/5 13D/G 10%+ Owner 3/4/5 13D/G	9.3% Reported 13D/G · 28 Sep 2026	— 592,593 shares	—	28 Sep 2026
BCLS Fund III Investments, LP	13D/G 13D/G	6.3% Reported 13D/G · 24 Sep 2026	— 6,728,970 shares	$0	24 Sep 2026
LAV Fund VI Opportunities, L.P.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	— 11,858,655 shares	—	28 Sep 2026
LAV Fund VI, L.P.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	— 11,858,655 shares	—	28 Sep 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

20,000

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders

Q3 2026 holders

Holder diff

Investor	Q2 2026 Shares	Q3 2026 Shares	Share Diff	Share Chg %	Q2 2026 value	Q3 2026 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend